CM
MBX

Caption Management’s MBX Biosciences MBX Stock Holding History

Caption Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,100
Closed -$792K – 2168
2025
Q4 		$792K Sell
25,100
-49,900
-67% -$1.21M 0.01% 1139
2025
Q3 		$1.31M Buy
+75,000
New +$1M 0.01% 1016

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Caption Management's MBX Position: Q4 2025 in Review

Caption Management sold out of MBX Biosciences (MBX) in Q4 2025, closing a stake of 20,000 shares — an estimated $485K sold.

Caption Management first reported a position in MBX in Q3 2025 and held it in 1 quarter. The position peaked at $350K in Q3 2025. 138 funds tracked by Wall St. Rank hold MBX as of Q4 2025.

  • Caption Management reported no remaining MBX Biosciences position as of Q4 2025 after selling out during the quarter.
  • Caption Management sold 20,000 MBX Biosciences shares in Q4 2025, an estimated $485K.
  • Caption Management first reported a position in MBX Biosciences in Q3 2025 and held it in 1 quarter.
  • Caption Management's MBX Biosciences position peaked at $350K in Q3 2025.
  • 138 funds tracked by Wall St. Rank held MBX Biosciences as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.